^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Temozolomide monotherapy is an efficacious alternative for elderly patients with O6-methylguanine DNA methyltransferase gene (MGMT) promoter methylation (HQE)...
Source:
Excerpt:
In elderly patients and a methylated MGMT promoter, exclusive TMZ chemotherapy may be considered, while (hypo-fractionated) radiotherapy is the treatment...
Source:
Excerpt:
ADULT GLIOMA: GLIOBLASTOMA….Adjuvant Treatment, KPS ≥60...Useful in Certain Circumstances...TMZ (for patients with MGMT promoter-methylated tumors and age >70 years)
Source:
Title:
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Excerpt:
...we enrolled patients with confirmed anaplastic astrocytoma or glioblastoma...MGMT promoter methylation was associated with longer overall survival than was unmethylated status (11·9 months [95% CI 9·0 to not reached] vs 8·2 months [7·0-10·0]; HR 0·62, 95% CI 0·42-0·91, p=0·014). EFS was longer in patients with MGMT promoter methylation who received temozolomide...
DOI:
https://doi.org/10.1016/S1470-2045(12)70164-X
Trial ID:
Source:
Title:
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
Excerpt:
...- Tissue available for the determination of MGMT promoter methylation in the primary tumor or from the recurrent tumor if a patient undergoes a surgical procedure at recurrence prior to study entry....
Trial ID:
Source:
Title:
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Excerpt:
...MGMT promoter methylation status (binary variable, determined by either Polymerase Chain reaction (PCR) or immunohistochemistry)`MGMT promoter methylation status (binary variable, determined by either PCR or immunohistochemistry)...
Trial ID:
More C2 evidence
Source:
Title:
A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastoma
Excerpt:
...Sufficient tissue representative of the disease available for central MGMT promoter methylation status (Phase I and II) and IDH status evaluation (Phase I).10. ...
Trial ID:
Source:
Title:
An efficacy and safety study of 2-OHOA in patients with glioblastoma
Excerpt:
...Centrally obtained MGMT promoter methylation status7. ...
Trial ID:
Source:
Title:
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Excerpt:
...Time to Disease Progression`Progression-free Survival at 6 Months`Radiographic Response (When Evaluable)`Median Overall Survival (OS) Based on the MGMT Promoter Methylation Status...
Trial ID:
Source:
Title:
Temozolomide in Elderly Patients With KPS < 70
Excerpt:
...Progression-free survival`adverse events`Health-related quality of life`Cognitive functioning`Efficacy according to MGMT Promoter methylation status...
Trial ID:
Source:
Title:
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Excerpt:
...- Subjects with sufficient biopsy material available to perform PCR analysis for MGMT promoter methylation must have tissue submitted to the designated laboratory for analysis....
Trial ID:
Less C2 evidence
Source:
Title:
Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide
Published date:
01/05/2021
Excerpt:
MGMTp methylation was found in 55.5% (35/63) of IDHWT and 84.6% (11/13) of IDHMUT, and as expected, MGMTp methylation was significantly associated with a better response to TMZ.
DOI:
https://doi.org/10.1007/s11060-020-03675-6
Source:
Title:
Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial
Excerpt:
Methylated tumors had longer mPFS (HR=0.57, 95% CI: 0.39-0.83, P=0.004) irrespectively to the study treatment.
DOI:
10.1200/JCO.2019.37
Trial ID:
Source:
Title:
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
Excerpt:
Progression‐free survival...IDH mutation...MGMT promoter methylation...and 1p19q codeletion were associated with increased PFS...IDH mutation, MGMT promoter methylation, and 1p19q codeletion were strongly correlated with increased OS (P<0.001, P<0.001, P=0.003, respectively)...
DOI:
10.1111/j.1349-7006.2011.02134.x
Source:
Title:
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
Excerpt:
methylation as detected by bisulphite sequencing seemed to be predictive of TMZ sensitivity in all six cell lines analysed (100%).
DOI:
10.1038/sj.bjc.6605712
Source:
Title:
Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
Excerpt:
The results of subgroup analysis showed that patients with methylated MGMT in extended group had significantly longer OS and PFS than those in control group; patients with IDH1 mutation benefited more from extended adjuvant TMZ chemotherapy than those with wild-type IDH1....The therapeutic schedule of extended adjuvant TMZ significantly prolonged OS and PFS of patients with newly diagnosed GBM regardless of p53 mutation status, and patients with different MGMT methylation, IDH1 mutation and Ki67 expression level benefited differently from extended adjuvant TMZ chemotherapy.
DOI:
10.3389/fonc.2022.1000501
Source:
Title:
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells
Published date:
05/07/2023
Excerpt:
The MGMT promoter methylation, migration, proliferation, and TMZ-response of the tumor cells were examined at different time points. The strong effects of TMZ treatment on the MGMT methylated cells were observed.
DOI:
https://doi.org/10.3390/ijms23095238
Source:
Title:
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome
Excerpt:
We found a heterogeneous response to temozolomide in the GSC culture cohort….TMZ sensitivity and MGMT methylation status were present (n=49), we found a moderate, statistically significant correlation between the variables (r=0.459, p=0.0009, Fig. 3A). Selecting only the cultures derived form TMZ-naïve patients (n=40) similarly revealed a moderate, statistically significant correlation (r=0.456, p=0.0031) between TMZ sensitivity and MGMT methylation status (Fig. 3B)....Contingency analyses of all (Fig. 3C) and the TMZ-naïve (Fig. 3D) cultures, further established the connection between MGMT promoter methylation and sensitivity to TMZ (p=0.0005 and p=0.0051, respectively).
DOI:
https://doi.org/10.1016/j.tranon.2022.101535
